Adaptimmune Therapeutics PLC Financial Ratios
ADAPY|FY2024 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2024 SEC 10-K data.
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2024)
Return on Equity
-597.6%
Profit Margin
-39.8%
Net Income / Revenue
Asset Turnover
0.72
Revenue / Total Assets
Equity Multiplier
20.76
Total Assets / Equity
Composite: -597.6% (reported: -597.6%)
Profitability
Liquidity
Current Ratio
2.92
Quick Ratio
2.80
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.72
Inventory Turnover
0.01
Days Sales Outstanding
3 days
As of FY2024 · SEC 10-K · Updated Jun 29, 2026
Earnings Quality
Accrual Ratio
+0.9%
-8.6pp YoY
Earnings are roughly in line with operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.